Ghrelin drives GH secretion during fasting in man.

OBJECTIVES In humans, fasting leads to elevated serum GH concentrations. Traditionally, changes in hypothalamic GH-releasing hormone and somatostatin release are considered as the main mechanisms that induce this elevated GH secretion during fasting. Ghrelin is an endogenous ligand of the GH secretagogue receptor and is synthesized in the stomach. As ghrelin administration in man stimulates GH release, while serum ghrelin concentrations are elevated during fasting in man, this increase in ghrelin levels might be another mechanism whereby fasting results in stimulation of GH release. DESIGN AND SUBJECTS In ten healthy non-obese males we performed a double-blind placebo-controlled crossover study comparing fasting with and fasting without GH receptor blockade. GH, ghrelin, insulin, glucose and free fatty acids were assessed. RESULTS While ghrelin levels do not vary considerably in the fed state, fasting rapidly induced a diurnal rhythm in ghrelin concentrations. These changes in serum ghrelin concentrations during fasting were followed by similar, profound changes in serum GH levels. The rapid development of a diurnal ghrelin rhythm could not be explained by changes in insulin, glucose, or free fatty acid levels. Compared with fasting without pegvisomant, fasting with pegvisomant did not change the ghrelin rhythm. CONCLUSIONS These data indicate that ghrelin is the main driving force behind the enhanced GH secretion during fasting.

[1]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[2]  K. Kangawa,et al.  Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor , 2001, Trends in Endocrinology & Metabolism.

[3]  C. Bowers Unnatural growth hormone-releasing peptide begets natural ghrelin. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  E. Ravussin,et al.  Circulating ghrelin levels are decreased in human obesity. , 2001, Diabetes.

[5]  M. Papotti,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatura , 2022 .

[6]  K. Nakao,et al.  Ghrelin strongly stimulates growth hormone release in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[7]  S. Bloom,et al.  The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. , 2000, Endocrinology.

[8]  M. Nakazato,et al.  Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. , 2000, Endocrinology.

[9]  N. Dits,et al.  Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice. , 2000, The Journal of endocrinology.

[10]  F. Casanueva,et al.  Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. , 2000, European journal of endocrinology.

[11]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[12]  K. Kangawa,et al.  Ghrelin stimulates gastric acid secretion and motility in rats. , 2000, Biochemical and biophysical research communications.

[13]  F. Casanueva,et al.  Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. , 2000, European journal of endocrinology.

[14]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[15]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.

[16]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[17]  M. Straume,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Growth Hormone (GH) Receptor Blockade with a PEG- Modified GH (B2036-PEG) Lowers Serum Insulin-Like Growth Factor-I but Does Not Acutely Stimula , 1998 .

[18]  J. Veldhuis,et al.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. , 1998, Endocrine reviews.

[19]  M. Thorner,et al.  Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. , 1998, The Journal of clinical endocrinology and metabolism.

[20]  Roy G. Smith,et al.  Peptidomimetic regulation of growth hormone secretion. , 1997, Endocrine reviews.

[21]  T. Wagner,et al.  Amino acid residues in the third alpha-helix of growth hormone involved in growth promoting activity. , 1995, Molecular endocrinology.

[22]  T. Wagner,et al.  Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Alberti,et al.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. , 1988, The Journal of clinical investigation.

[24]  B. Vialettes,et al.  Low Plasma Levels of Pancreatic Polypeptide in Obesity , 1980, Diabetes.

[25]  J. A. Hedo,et al.  Fluctuations of Human Pancreatic Polypeptide in Plasma: Effect of Normal Food Ingestion and Fasting 1 , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.